MIT - Cellbiocan shows its progress in the fight against cancer

Mon, 05/07/2018

The biomedical company Cellbiocán has been distinguished by the Massachusetts Institute of Technology (MIT) and, endorsed by the Foundation for Health Innovation and Prospective in Spain (Fipse), will participate in the third edition of the Fipse International Mentoring Program that will begin next July in Boston (United States).

Cellbiocan, a company in which Grupo Tirso participates, the Igualatorio Médico, Sodercán, and a researcher from the Marqués de Valdecilla Research Institute (Idival), has been chosen along with five other R + D + i projects for its nanoplasmonic sensor for the Detection of tumor cells in the blood of patients with cancer that is being applied at the Marqués de Valdecilla University Hospital.

The selection of the proposals was made days ago by a team of evaluators from MIT in the framework of the conference 'Impulse of the biomedical innovation ecosystem in Spain' organized by FIPSE and MIT itself at the Carlos III Health Institute in Madrid.


Grupo Tirso, Cellbiocan, MIT, CTC's, Tumor, Oncology, cancer, hospital